GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (FRA:YDO1) » Definitions » Selling, General, & Admin. Expense
中文

Madrigal Pharmaceuticals (FRA:YDO1) Selling, General, & Admin. Expense : €100.10 Mil (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Madrigal Pharmaceuticals's selling, general, & admin. expense for the three months ended in Dec. 2023 was €42.67 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was €100.10 Mil.


Madrigal Pharmaceuticals Selling, General, & Admin. Expense Historical Data

The historical data trend for Madrigal Pharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Madrigal Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.38 17.97 33.03 45.44 99.17

Madrigal Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.74 15.11 16.47 25.85 42.67

Competitive Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals Selling, General, & Admin. Expense Distribution

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Selling, General, & Admin. Expense falls into.



Madrigal Pharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €100.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Madrigal Pharmaceuticals  (FRA:YDO1) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Madrigal Pharmaceuticals Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Madrigal Pharmaceuticals (FRA:YDO1) Business Description

Traded in Other Exchanges
Address
200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Madrigal Pharmaceuticals (FRA:YDO1) Headlines

No Headlines